<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01797198</url>
  </required_header>
  <id_info>
    <org_study_id>3652-CL-0006</org_study_id>
    <secondary_id>2011-002874-21</secondary_id>
    <nct_id>NCT01797198</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Effect of Multiple Doses of Gemfribozil on a Single Dose of ASP3652, and to Assess the Effects of Multiple Doses of ASP3652 on a Single Dose of Repaglinide in the Body of Healthy Subjects</brief_title>
  <official_title>An Open Label, Drug-drug Interaction Study to Assess the Effect of Multiple Doses of Gemfibrozil on the Single Dose Pharmacokinetics of ASP3652 and to Assess the Effect of Multiple Doses of ASP3652 on the Single Dose Pharmacokinetics of Repaglinide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Europe B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ASP3652 is being investigated as a novel treatment for chronic pelvic pain. This is a
      two-part study to investigate the drug-drug potential of ASP3652.

      Part I of the study evaluates the effect of gemfibrozil twice daily on the single dose of
      ASP3652.

      Part 2 evaluates the effect of multiple doses of ASP3652 twice daily on the single dose of
      repaglinide.

      Subjects participating in one part of the study may not participate in the other part.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1:

      On Day 1, a single dose of ASP3652 is administered. After a wash-out period of 3 days, bid
      (twice daily) dosing of gemfibrozil starts on Day 4 and continues for 7 days until Day 10. On
      Day 8 (the 5th day of gemfibrozil administration), a single dose of ASP3652 is administered
      one hour after the morning dose of gemfibrozil.

      Part 2:

      On Day 1, a single dose of repaglinide is administered. After a wash-out period of 3 days,
      bid dosing of ASP3652 starts on Day 4 and continues for 7 days until Day 10. On Day 8 (the
      5th day of ASP3652 administration), a single dose of repaglinide is administered one hour
      after the morning dose of ASP3652.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of multiple doses of gemfibrozil on the Pharmacokinetics (PK) of a single dose of ASP3652 (plasma) and metabolites H1/H2/H3</measure>
    <time_frame>Days 1 - 11</time_frame>
    <description>Part 1: Maximum concentration (Cmax), AUClast and AUCinf</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of multiple doses of ASP3652 on the PK of a single dose of repaglinide and metabolite M4 (plasma)</measure>
    <time_frame>Days 1 - 10</time_frame>
    <description>Part 2: Cmax, AUClast, AUCinf, and the ratio AUC(M4) / AUC(repaglinide)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the safety of single and multiple doses of ASP3652 alone and in combination with gemfibrozil or repaglinide</measure>
    <time_frame>Screening - End of Study Visit (7-14 days after (early) discharge)</time_frame>
    <description>Both Parts: Vital signs, physical examination, adverse events, electrocardiogram, clinical laboratory assessments, body temperature, Bond and Lader Visual Analogue Scale (VAS) questionnaire, Physician's Withdrawal Checklist (PWC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of multiple doses of gemfibrozil on the PK of a single dose of ASP3652 (plasma), metabolites H1/H2/H3 and Parent gemfibrozil and gemfibrozil-1-O-ß-glucuronide (plasma)</measure>
    <time_frame>Days 1-11</time_frame>
    <description>Part 1: tmax, tlag, t1/2, Vz/F, CL/F, Cmax, morning and evening Ctrough, tmax, AUCtau and CL/F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of multiple doses of ASP3652 on the PK of a single dose of repaglinide</measure>
    <time_frame>Days 1-10</time_frame>
    <description>Part 2: tmax, tlag, t1/2, Vz/F, CL/F, Cmax, morning and evening Ctrough, tmax, AUCtau and CL/F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of ASP3652 on the Pharmacodynamics (PD) of repaglinide by comparing the effect of repaglinide on blood glucose levels in the presence and absence of ASP3652</measure>
    <time_frame>Days 1-10</time_frame>
    <description>Part 2: Baseline blood glucose concentration, minimum blood glucose concentration, and mean blood glucose concentration from 0 to 9h after dosing of repaglinide</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Drug-Drug Interaction (DDI)</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>gemfibrozil + ASP3652</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of gemfibrozil and single dose of ASP3652</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP3652 + repaglinide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of ASP3652 and the single dose of repaglinide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP3652</intervention_name>
    <description>Oral</description>
    <arm_group_label>gemfibrozil + ASP3652</arm_group_label>
    <arm_group_label>ASP3652 + repaglinide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemfibrozil</intervention_name>
    <description>Oral</description>
    <arm_group_label>gemfibrozil + ASP3652</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Repaglinide</intervention_name>
    <description>Oral</description>
    <arm_group_label>ASP3652 + repaglinide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is white and of Caucasian origin.

          -  Body Mass Index more than or equal to 18.5 and less than 30.0 kg/m2.

          -  Male subjects must agree to practice an effective contraceptive method with female
             sexual partners to prevent pregnancy.

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to ASP3652, repaglinide and/or gemfibrozil, or any
             components of the formulation used.

          -  Any of the liver function tests (ALT, AST, γ-GT, TBL and ALP) above the upper limit of
             normal. In such case the sample may be repeated once.

          -  Regular use of any inducer of metabolism (e.g. barbiturates, Rifampicin) in the 3
             months prior to admission to the Clinical Unit.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Manager</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PAREXEL Early Phase Clinical Unit</name>
      <address>
        <city>Harrow</city>
        <zip>HA1 3U</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2013</study_first_submitted>
  <study_first_submitted_qc>February 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2013</study_first_posted>
  <last_update_submitted>February 20, 2013</last_update_submitted>
  <last_update_submitted_qc>February 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>ASP3652</keyword>
  <keyword>Gemfibrozil</keyword>
  <keyword>Repaglinide</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Repaglinide</mesh_term>
    <mesh_term>Gemfibrozil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

